Back to top

biotechs: Archive

Zacks Equity Research

AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa

AZN secures US and EU approval for Klygefa, a once-weekly gMG treatment that offers patients greater convenience.

AZNPositive Net Change JNJPositive Net Change AMGNPositive Net Change ARGXNegative Net Change

Zacks Equity Research

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure shares rally 17.5% as FDA grants Priority Review to its Huntington's disease gene therapy, but it remains to be seen if clinical and regulatory progress can sustain momentum.

QURENegative Net Change COLLNegative Net Change AMRXNegative Net Change

Ekta Bagri

Can BMY Sustain Growth in Its Cardiovascular Franchise?

Bristol Myers Squibb is expanding Camzyos??? reach, benefiting from Eliquis??? strong sales and advancing milvexian to drive cardiovascular growth.

BMYPositive Net Change CYTKPositive Net Change EWTXNegative Net Change

Zacks Equity Research

BIAF Stock Dips Post Q3 Earnings Despite Rising Test Demand, Sales Down

bioAffinity's third-quarter 2026 results show weaker laboratory revenues and wider losses despite rising CyPath Lung test demand and growing physician adoption.

BIAFNegative Net Change

Zacks Equity Research

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.

MRNANegative Net Change SNYPositive Net Change PFENegative Net Change MRKPositive Net Change

Zacks Equity Research

CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.

CRMDNegative Net Change ADPTNegative Net Change ACIUNegative Net Change AMRXNegative Net Change

Ahan Chakraborty

4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day

LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.

NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change

Kevin Cook

Bear of the Day: Boston Scientific (BSX)

BSX growth continues to flatline but expects 2027 to mark cycle's trough, 2028 recovery driven by new launches

BSXNegative Net Change

Sundeep Ganoria

How Did AbbVie's Immunology Franchise Fare in Q3?

ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline.

ABBVPositive Net Change JNJPositive Net Change LLYPositive Net Change

Sundeep Ganoria

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?

Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.

MRNANegative Net Change PFENegative Net Change MRKPositive Net Change BNTXNegative Net Change